Systemic radionuclide therapy with Samarium-153-EDTMP for painful bone metastases.
We introduced in 33 patients intravenous systemic administration of Samarium-153-EDTMP. Average age of patients was 61 years, range from 29 to 83 years. Mean application activity was 39 MBq per kg of patient's body weight. One month after this administration we observed a significant analgetic effect in 37% of patients, partial analgetic effect in 37% and we noticed no effect in 26% of patients. Three months after administration we observed a significant analgetic effect in 45% of patients, a partial effect in 26% and no effect in 29% of patients. The withdrawal of bone pain was joined with an improvement of the patient's mobility and with the decrease of the necessary dose of anodynes and nonsteroid analgetics.